- Email: [email protected]
Ulcerative diseases of animals with an infectious aetiology
Quarterly
Dental
Review
MEBUS C. A. Ulcerative diseases of animals with an in fectious aetiology, J. Oral Pathol. 7 (1978) 365-371.
263
tetracycline also experienced a reduction in size, duration and pain. No side effects were observed and the authors propose that the use of tetracycline in this way is beneficral in aphthous stomatitis.
Five specific viral diseases of cattle are considered in detail since their study might be helpful in the elucidatron of ulcerative
A. M. Skelly
oral disease in man. Oral manifestations of systemic viral disease in cattle occur as either vesicular or ulcerative lesions. For each of the 5 drseases, foot and mouth disease, vesicular stomatitis, rinderpest, bovine virus diarrhoea and malignant catarrhal fever, the author shows that whereas the clinical appearances may be grossly similar, histological examination shows that the lesions affect different levels within the epithelium and that each has a distinctive destructive pattern. A. M. Skelly
SAMPSON D. Studies on levamisole, a potentially useful drug in the treatment of Behqet’s syndrome, J. Oral Pathol. 7 (1978) 383-386.
GRAYKOWSKI E. A. and KINGMAN A. Double-blind trial of tetracycline in recurrent aphthous ulceration, J. Oral Pafhol. 7 (1978) 376-382. Twenty-five subjects took part in a 20-week double-blind trial of tetracycline suspension for the treatment of recurrent aphthous ulceration. No attempt was made to distinguish the type of aphthae In any individual patient but those suffering from any other mucocutaneous condition were excluded. Baseline data including routine physical examination and haematological investigation was collected and the subjects divided into two groups. The subjects were given either a suspension of tetracycline 250 mg/5 ml or a placebo and instructed to take the suspension-l teaspoon (5 ml) 4 times a day for 20 doses-at the onset of ulceration. The suspension was used as a 2 min mouth rinse before swallowing. Individual subjects kept a daily record of incidence, size, duration and degree of pain associated with any ulceration. A weekly control examination was caried out by the invstigators. On completion it was found that all subjects had experienced a reduction in incidence of ulceration-indicating a significant placebo effect in the treatment of this condition, but that those receiving
Laboratory the action
experiments were carried out on of the anthelmintic drug, levam-
isole, as an immunopotentiating agentwith a view to determining its likely effectiveness as a therapeutic agent in Behcet’s syndrome. First, levamisole was shown to augment the response of human peripheral blood lymphocytes in vitro by comparing the mitogenic response to known plant mitogens in culture with differing doses of levamisole. Doses of 0.6-0.8 fig/ml lead to an optimal increase in mitoses but at concentrations over 1 pglml reactivity to mitogens tended to be depressed, Second, varying oral doses of levamisole were given to rats with dimethylbenzanthraceneinduced breast cancer. Tumour growth was assessed by measuring mean tumour diameter at intervals. In addition, after killing the animals the mitogenic response of spleen lymphocytes was examined. Doses of 2-4 mg/kg resulted in decrease in tumour size but at 8 mg/kg tumours increase at a rate equal to or faster than those of control animals. The author postulates that levamisole may be effective in controlling the lesions of Behcet’s syndrome but that careful dose monitoring is essential as exacerbation of the disease might result from too large a dose. A. M. Skelly
MILLER M. F., SILVERT M. E., LASTER L. L., GREEN P. and SHIP I. I. Effect of levamisole on the incidence and prevalence of recurrent aphthous stomatitis. J. Oral Pathol. 7 (1978) 387-392. A double-blind trial was carried out on 20 subjects with severe RAS (defined as more
Dental
Review
MEBUS C. A. Ulcerative diseases of animals with an in fectious aetiology, J. Oral Pathol. 7 (1978) 365-371.
263
tetracycline also experienced a reduction in size, duration and pain. No side effects were observed and the authors propose that the use of tetracycline in this way is beneficral in aphthous stomatitis.
Five specific viral diseases of cattle are considered in detail since their study might be helpful in the elucidatron of ulcerative
A. M. Skelly
oral disease in man. Oral manifestations of systemic viral disease in cattle occur as either vesicular or ulcerative lesions. For each of the 5 drseases, foot and mouth disease, vesicular stomatitis, rinderpest, bovine virus diarrhoea and malignant catarrhal fever, the author shows that whereas the clinical appearances may be grossly similar, histological examination shows that the lesions affect different levels within the epithelium and that each has a distinctive destructive pattern. A. M. Skelly
SAMPSON D. Studies on levamisole, a potentially useful drug in the treatment of Behqet’s syndrome, J. Oral Pathol. 7 (1978) 383-386.
GRAYKOWSKI E. A. and KINGMAN A. Double-blind trial of tetracycline in recurrent aphthous ulceration, J. Oral Pafhol. 7 (1978) 376-382. Twenty-five subjects took part in a 20-week double-blind trial of tetracycline suspension for the treatment of recurrent aphthous ulceration. No attempt was made to distinguish the type of aphthae In any individual patient but those suffering from any other mucocutaneous condition were excluded. Baseline data including routine physical examination and haematological investigation was collected and the subjects divided into two groups. The subjects were given either a suspension of tetracycline 250 mg/5 ml or a placebo and instructed to take the suspension-l teaspoon (5 ml) 4 times a day for 20 doses-at the onset of ulceration. The suspension was used as a 2 min mouth rinse before swallowing. Individual subjects kept a daily record of incidence, size, duration and degree of pain associated with any ulceration. A weekly control examination was caried out by the invstigators. On completion it was found that all subjects had experienced a reduction in incidence of ulceration-indicating a significant placebo effect in the treatment of this condition, but that those receiving
Laboratory the action
experiments were carried out on of the anthelmintic drug, levam-
isole, as an immunopotentiating agentwith a view to determining its likely effectiveness as a therapeutic agent in Behcet’s syndrome. First, levamisole was shown to augment the response of human peripheral blood lymphocytes in vitro by comparing the mitogenic response to known plant mitogens in culture with differing doses of levamisole. Doses of 0.6-0.8 fig/ml lead to an optimal increase in mitoses but at concentrations over 1 pglml reactivity to mitogens tended to be depressed, Second, varying oral doses of levamisole were given to rats with dimethylbenzanthraceneinduced breast cancer. Tumour growth was assessed by measuring mean tumour diameter at intervals. In addition, after killing the animals the mitogenic response of spleen lymphocytes was examined. Doses of 2-4 mg/kg resulted in decrease in tumour size but at 8 mg/kg tumours increase at a rate equal to or faster than those of control animals. The author postulates that levamisole may be effective in controlling the lesions of Behcet’s syndrome but that careful dose monitoring is essential as exacerbation of the disease might result from too large a dose. A. M. Skelly
MILLER M. F., SILVERT M. E., LASTER L. L., GREEN P. and SHIP I. I. Effect of levamisole on the incidence and prevalence of recurrent aphthous stomatitis. J. Oral Pathol. 7 (1978) 387-392. A double-blind trial was carried out on 20 subjects with severe RAS (defined as more